Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients
Ten months earlier, the Phase 3 Exenatide-PD3 trial had reached the same conclusion in Parkinsons disease: no effect on progression across 194 patients followed for 96 weeks, with no treatment difference on dopamine-transporter imaging in the trials imaging substudy [2]
Based on the estimated 3.8 million Part D enrollees eligible for the Medicare GLP-1 Bridge as of 2023, if 10% to 25% participate in Bridge from when the program launches in July 2026 and fill a prescription each month for the 18-month duration of the program, the cost to Medicare would be $1.3 billion to $3.3 billion (at a net monthly cost of $245 minus the $50 beneficiary copay)
All publications available within PubMed, Google Scholar, and Cochrane databases were reviewed for peer-reviewed journal articles, clinical trial data, and evidence-based reviews
